Hybridoma cell line is a product of fusion
**Core Concept**
Hybridoma technology is a laboratory technique used to produce large quantities of monoclonal antibodies. This involves the fusion of two cells: a B lymphocyte (antibody-producing cell) and a myeloma cell (cancerous plasma cell). The resulting hybridoma cell line is capable of producing a single type of antibody with unique antigen-binding properties.
**Why the Correct Answer is Right**
The correct answer is a product of fusion because the hybridoma cell line is created by fusing a B lymphocyte with a myeloma cell. This fusion event allows the B lymphocyte to retain its ability to produce antibodies, while the myeloma cell provides the stability and ability to grow indefinitely in culture. The resulting hybridoma cell line can then be cultured and expanded to produce large quantities of the desired monoclonal antibody.
**Why Each Wrong Option is Incorrect**
* **Option A:** Not applicable, as the question does not provide any context for this option.
* **Option B:** Incorrect because hybridoma technology involves the fusion of two cells, not the fusion of a single cell with a foreign substance.
* **Option C:** Incorrect because a hybridoma cell line is not simply a product of cell division, but rather the result of a specific fusion event between two cells.
* **Option D:** Incorrect because a hybridoma cell line is not a product of gene expression, but rather the result of a cell fusion event.
**Clinical Pearl / High-Yield Fact**
Hybridoma technology has revolutionized the field of immunology and has led to the development of numerous monoclonal antibodies used in clinical practice. These antibodies are highly specific and can be used to diagnose and treat a wide range of diseases, including certain types of cancer and autoimmune disorders.
**Correct Answer:** D.